Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Moleculin Biotech, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 21 | 23 | +2 |
| Shares | 464.7K | 1.48M | +1.01M (+218.1%) |
| Value | $790.0K | $1.44M | +$648.9K (+82.1%) |
New holders (6)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cetera Investment Advisers | 70,000 | $68.2K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 12,781 | $12.0K | 0.00% |
| XTX Topco Ltd | 11,575 | $11.3K | 0.00% |
| Citigroup Inc | 2,788 | $2.71K | 0.00% |
| Barclays PLC | 344 | $335 | 0.00% |
| FMR LLC | 34 | $33 | 0.00% |
Sold out (4)
Institutions that held Moleculin Biotech, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Renaissance Technologies LLC | 11,496 | $19.5K |
| UBS Group AG | 8,939 | $15.2K |
| Atticus Wealth Management, LLC | 2,784 | $4.73K |
| Kestra Investment Management, LLC | 25 | $43 |